People: Vision Sciences Inc (VSCI.O)

VSCI.O on Consolidated Issue listed on NASDAQ Capital Market

1.17USD
14 Jul 2014
Price Change (% chg)

$0.00 (+0.43%)
Prev Close
$1.16
Open
$1.17
Day's High
$1.17
Day's Low
$1.17
Volume
290
Avg. Vol
30,689
52-wk High
$1.75
52-wk Low
$0.78

Search Stocks

Summary

Name Age Since Current Position

Lewis Pell

70 2013 Chairman of the Board

Howard Zauberman

60 2013 President, Chief Executive Officer, Director

Gary Siegel

56 2014 Principal Financial Officer, Principal Accounting Officer, Vice President - Finance

Mark Landman

58 2007 Vice President - Disposables Operations

Jitendra Patel

59 2000 Vice President - Industrial Division

David Anderson

2005 Independent Director

Katsumi Oneda

75 2005 Independent Director

Cheryl Pegus

48 2013 Independent Director

John Rydzewski

60 2009 Independent Director

Biographies

Name Description

Lewis Pell

Mr. Lewis C. Pell is Chairman of the Board of Vision Sciences Inc., since October 2005. Prior to that, Mr. Pell served as Vice-Chairman of Board of Directors since 1992. Mr. Pell is a founder or co-founder and chairman and director of several privately held medical device companies and is the chairman of Photomedex, Inc., a publicly-traded dermatology company.

Howard Zauberman

Mr. Howard I. Zauberman is President, Chief Executive Officer, Director of Vision Sciences, Inc. Mr. Zauberman, 60, has over 30 years of experience as a leader in the medical products industry. Prior to joining Vision-Sciences in May 2013, Mr. Zauberman was Vice President of Business Development at Henry Schein, Inc., a leading global healthcare distributor serving office based medical practitioners, from 2005 through 2012. Mr. Zauberman also served as a Special Venture Partner at Galen Partners, a healthcare growth equity and late stage venture capital firm, focused on technology enabled services, medical devices and specialty pharmaceuticals. Prior to this, Mr. Zauberman held senior management positions at ETHICON, Inc. a Johnson & Johnson company and Pfizer, Inc. Mr. Zauberman has a Masters of Engineering Management from Northwestern University, a Bachelor of Science from Columbia University in mechanical engineering and a Bachelors degree from Queens College.

Gary Siegel

Mr. Gary Siegel is Principal Financial Officer, Principal Accounting Officer, Vice President - Finance of the Company. Prior to joining the Company, Mr. Siegel was Vice President of Finance at Genta Incorporated. Previous positions during his ten years at Genta included Senior Director, Financial Services and Director, Financial Services. He also served as Genta’s Principal Financial Officer and Principal Accounting Officer and Corporate Secretary. Prior to joining Genta, Mr. Siegel worked for two years at Geller & Company, a private consulting firm, where he led the management reporting for a multi-billion dollar client. He also spent 18 years at Warner-Lambert Company and Pfizer Inc., where he held positions of progressively increasing levels of responsibility including Director, Corporate Finance and Director, Financial Planning & Reporting. Mr. Siegel holds a Master of Business Administration from Carnegie-Mellon University and a Bachelor of Science in accounting from the University of Connecticut.

Mark Landman

Mr. Mark S. Landman serves as Vice President - Disposables Operations of Vision Sciences Inc. He served as Vice President of Medical Division since July 1999. Mr. Landman joined the company from Boston Scientific in January 1991 and served in a variety of roles in product development, project management, manufacturing engineering, and material control from that date to July 1999.

Jitendra Patel

Mr. Jitendra Patel serves as Vice President - Industrial Division of Vision Sciences Inc. From August 1995 to July 2000, he served as the Manager of Sales and Marketing for that division.

David Anderson

Mr. David W. Anderson is Independent Director of Vision Sciences Inc. He Anderson has served as President, Chief Executive Officer and director of Gentis, Inc. since 2004. Prior to that, Mr. Anderson was the President, Chief Executive Officer and director of Sterilox Technologies, Inc. from 2000 to 2004. Mr. Anderson is a director of Photomedex Inc., Inion Ltd. and several private companies. Mr. Anderson serves on the company's Audit, Governance and Nominating, and Compensation Committees.

Katsumi Oneda

Mr. Katsumi Oneda is an Independent Director of Vision Sciences Inc. He is a co-founder of Vision-Sciences and served as Chairman of the Board of Directors from 1990 to 1991 and again from 1993 to 2005. From 1993 through 2003, he also served as President and Chief Executive Officer. He served as Vice-Chairman of Board from 1992 to 1993 Mr. Oneda is a director of Photomedex, Inc. and of a private company.

Cheryl Pegus

Dr. Cheryl Pegus, M.D., MPH, is appointed as Independent Director of Vision Sciences, Inc. Dr. Pegus is a Director of Glytec, a glycemic clinical software company and Strategic Advisor to HealthFleet, Inc, an online interactive prevention company. She is the 2013 President-Elect and a member of the Board of the American Heart Association (AHA) Founder’s Affiliate. Previously, she was the Chief Medical Officer for Walgreens. She has served as the General Manager and Chief Medical Officer for SymCare Personalized Health Solutions, Inc., and the Head of Clinical Products for Aetna’s Medical Products Business Unit. Dr. Pegus also served as the Medical Director for the Cardiovascular Risk Factors Group at Pfizer Pharmaceuticals. She is a Member of the Dean’s Circle at Weill Cornell Medical College. She received an M.P.H. from Columbia University School of Public Health, an M.D. from Cornell University Medical College and completed her internal medicine residency and cardiology fellowship at New York Hospital-Cornell.

John Rydzewski

Mr. John J. Rydzewski, CPA, is Independent Director of Vision Sciences Inc., since June 2009. He is the Executive Chairman of Enumeral Biomedical Corp., a privately-held company engaged in the discovery of native human monoclonal antibodies for use in disease diagnosis and treatment. Prior to joining Enumeral in October 2011, he was a Managing Director of Christofferson, Robb & Co. where he was responsible for life science investments since 2006. Mr. Rydzewski was previously a healthcare investment banker and a manager at Price, Waterhouse & Co. He currently serves as Executive Chairman of Enumeral Biomedical Corp., Director of Fidelis Care New York, and Vice Chairman of RAND Health, the healthcare policy research unit of the RAND Corporation. He received both MBA and BS degrees from The Wharton School of the University of Pennsylvania and he obtained his C.P.A license in Missouri. Mr. Rydzewski serves on Audit, Governance and Nominating, and Compensation Committees.

Basic Compensation

Name Fiscal Year Total

Lewis Pell

110,814

Howard Zauberman

590,886

Gary Siegel

--

Mark Landman

170,000

Jitendra Patel

159,500

David Anderson

--

Katsumi Oneda

109,200

Cheryl Pegus

--

John Rydzewski

--
As Of 30 Mar 2013

Options Compensation

Search Stocks